Acute tacrolimus nephrotoxicity in kidney transplanted patients - from kidney biopsy to urinary markers of acute kidney injury: a case report
Abstract
##plugins.themes.bootstrap3.article.details##
KIM-1, NGAL, CysC, IP-10, kidney transplant
2. Rabbat C, Kevine E, Thorpe J, Russel D, Churchill D. Comparison of mortality risk for dialysis patients and cadaveric first renal transplant recipients in Ontario, Canada. J Am Soc Nephrol 2000; 11:917-922.
3. Halawa A. The early diagnosis of acute renal graft dysfunction. A challenge we face. The role of novel biomarkers. Ann Transplant 2011; 16(1):90-98.
4. Srinivas T, Meier-Kriesche H-U. Minimizing Immunosuppression, an alternative approach to reducing side effects: objectives and interim results. Clin J Am Soc Nephrol 2008; 3(Supll 2):S101-S116.
5. Lieberman KV, Lin WG, Reisman R. FK506 is a direct glomeruloconstrictor as determined by electrical resistant pulse sizing. Transplant Proc 1991; 23:3119-3120.
6. Bertram L, Kasiske L, Martin G, Zeier A, et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int 2009.
7. Kjedsen L, Johnsen A, Sengelov H, Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 1993; 268:10425-10432.
8. Ling W, Zhaohui N, Ben H, Leyi G. Urinary IL-18 and NGAL as early predictive biomarkers in contrast-induced nephropathy after coronary angiography. Nephron Clin Pract 2008; 108: 176-181.
9. Makris K, Markou N, Evodia E, et al. Urinary NGAL as an early marker of acute kidney injury in critically ill multiple trauma patients. Clin Chem Lab Med 2009; 47:79-82.
10. Ichimura T, Bonventre JV, Bailly V, et al. Kidney injury molecule-1(KIM-1), a Putative Epithelial Cell Adhesion Molecule Containing a novel immunoglobulin domain, is up-regulated in renal cells after Injury. J Biol Chem 1998; 273(7):4135-4142.
11. Huo W, Zhang K, Nie Z, Li Q, Jin F. Kidney injury molecule-1 (KIM-1): a novel kidney-specific injury molecule playing potential double edged functions in kidney injury. Transplant Rev (Orlando) 2010; 23(3):143-146.
12. Liangos O, Tighiouart H, Perianayagam M, et al. Comparative analysis of urinary biomarkers for early detection of acute kidney injury following cardiopulmonary bypass. Biomarkers 2009; 14(6):423-443.
13. Parikh CR, Mishra J, Thiessen-Philbrook H, Dursun B, Ma Q, Kelly C, Dent C Devarajan P, Edelstein CL. Urinary Il-18 is an early predictive biomarker in acute kidney injury after cardiac surgery. Kidney Int 2006; 70(1):199-203.
14. Booth V, Keizer DW, Kamphuis M, Clark-Lewis I, Sykes B. The CXCR3 binding chemokine IP-10/CXCL10: structure and receptor interactions. Biochemistry 2002; 41(33):10418-10425.
15. Jackson JA, Kim EJ, Begley B, Cheeseman J, et al. Urinary Chemokines CXCL9 and CXCL10 are non-invasive markers of renal allograft rejection and BK viral infection. Am J Transplant 2011; 11(10):2228-2234.
16. Conti M, Moutereau S, Zater M, et al. Urinary cystatin C as a specific marker of tubular dysfunction. Clin Chem Lab Med 2006; 44(3):288-291.
17. Dumea R, Siriopol D, Hogas S, Mititiuc I, Covic A. Procalcitonin: diagnostic value in systemic infections in chronic kidney disease or transplant patients. Int Urol Nephrol 2014; 46(2):461-468.
18. Beqja-Lika A, Bulo-Kasneci A, Refatllari E, et al. Serum procalcitonine levels as an early diagnostic indicator of sepsis. Mat Soc Med 2013; 25(1):23-25.
19. Covic A. Nephrology. Theoretical and practical principles, 2nd Edition. Iasi: Demiurg 2011.
20. Kramer BK, Montagnino G, Del Castillo D, et al. Efficacy and safety of tacrolimus compared with cyclosporine A microemulsion in renal transplantation: 2 years follow- up results. Nephrol Dial Transplant 2005; 20(5):968-973.
21. Hardinger KL, Bohl DL, Schnitzler MA, et al. A randomized, prospective, pharmacoeconomic trial of tacrolimus versus cyclosporine in combination with thymoglobulin in renal transplant recipients. Transplantation 2005; 80: 41-46.
22. Knops N, Levtchenko E, Van den Heuvel B, Kuypers D. From gut to kidney: transporting and metabolizing calcineurin-inhibitors in solid organ transplantation. Int J Pharm 2013; 452: 14-35.
23. Hocherl K, Dreher F, Vitzhum H, Kohler J, Kurtz A. Cyclosoprine A suppresses cyclooxygenase-2 expression in the rat kidney. J Am Soc Nephrol 2002; 13:2427-2436.
24. Cortina C, Trojer R, Waldeger S, Schneeberger S, Gut N, Hofer J. De novo tacrolimus-induced thrombotic microangiopathy in the early stage after transplantation successfully treated with conversion to everolimus. Pediatric Nephrology 2015; 30(4):693-697.
25. Naesens m, Kuypers D, Sarwal M. Calcineurin Inhibitor Nephrotoxicity. Clin J Am Soc Nephrol 2009; 4:481-508.
26. Hall I, Koyner J, Doshi M, Marcus R, Parikh C. Urine Cystatin C as a biomarker of proximal tubular function immediately after kidney transplantation. Am J Nephrol 2011; 33:407-413.
27. Zhang PL, Rothblum LI, Han WK, Blasick TM, Potdar S, Bonventre JV. Kidney Injury Molecule-1 expression in transplant biopsies is a sensitive measure of cell injury. Kidney Int 2008; 73(5):608-614.
28. Yadav B, Prasad N, Agrawal V, et al. Urinary kidney injury molecule-1 can predict delayed graft function in living donor renal allograft recipients. Nephrology (Carlton) 2015; 19.doi.10.1111
29. Song L, Xue L, Yu J, Zhao J, Zhang W, Fu Y. Kidney injury molecule-1 expression is closely associated with renal allograft damage. Bosn J Basic Med Sci 2013; 13(3):170-174.
30. Parikh CR, Jani A, Mishra J, et al. Urine NGAL and IL-18 are predictive biomarkers for delayed graft function following kidney transplantation. Am J Transplant 2006; 6:1639-1645.
31. Fonseca I, Oliveira JC, Almeida M, et al. Neutrophil Gelatinase-Associated Lipocalin in kidney transplantation is an early marker of graft dysfunction and is associated with one year renal function. Journal of Transplantation 2013;dx.doi.10.1155/650123.
32. Tsuchimoto A, Shinke H, Uesugi M, et al. Urinary Neutrophil Gelatinase-Associated Lipocalin; a useful biomarker for tacrolimus-induced acute kidney injury in liver transplant patients. Plos One 2014; 9(10):e110527.
Archive of Clinical Cases is protected by copyright and may be used in accordance with copyright and other applicable laws. Content available at www.clinicalcases.eu and our digital applications is intended for personal noncommercial use.
Authors who submit a manuscript for publication in Archive of Clinical Cases agree to the following terms: a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) only after the final version of the manuscript was accepted and published, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). d. It is compulsory that before submission authors ensure that their work was not published in any other medical journals or pending acceptance for publication and that "Archives of Clinical Cases" is the only beneficiary at that moment if their work/case will be accepted by us.
Guidelines for linking to www.clinicalcases.eu a. The main purpose of the site linking to the Archive of Clinical Casess site should be educational. b. Links should be made to the Archive of Clinical Casess home page (www.clinicalcases.eu) or to the articles abstract. c. It is forbidden to use the Archive of Clinical Casess cover by outside organizations unless permission has been granted in advance, notifying our Secretary. d. Material owned by the Archive of Clinical Cases (including the name, logo, cover, and text) may not be used in any manner that may induce the idea or suggest that the Archive of Clinical Cases is in some way recommending a specific company, product or service. e. You must not use or allow others to access or use, all or any part of our Site or the contents and/or applications on it for commercial purposes without our permission. To seek permission to do anything prohibited by or not contained in these TERMS, or which requires our prior consent or agreement, you can contact us.